Endo Pharmaceuticals announced a partnership with specialty pharma ProStrakan to commercialize the latter’s Fortesta (testosterone gel) 2% in the US. FDA is currently reviewing an NDA for Fortesta, a hormone replacement therapy for male hypogonadism – a condition whereby male sex glands produce too little testosterone. Endo plans to market the product, upon FDA approval, alongside Nebido, an Endo hormone therapy injectable also under review at FDA.
Behavioral science agency MicroMass Communications announced a partnership with Worldwide Partners, Inc. (WPI) to increase its reach internationally. WPI’s network consists of 94 agencies for clients in 54 countries around the world. WPI is based in Denver, CO.
Abbott will collaborate with Pfizer on a molecular diagnostic test for the screening of non-small cell lung cancer tumors for the presence of gene rearrangements, according to a joint company statement. Abbott’s molecular diagnostics business, headquartered in Des Plaines, IL, will develop the diagnostic tool necessary for identifying patients eligible for Pfizer’s investigational agent (PF-02341066) that selectively targets cancer-causing genes, according to the statement.
